Metal Ion Stimulation of Phospholipase D-Like Activity of Isolated Rat Intestinal Mitochondria M

Total Page:16

File Type:pdf, Size:1020Kb

Metal Ion Stimulation of Phospholipase D-Like Activity of Isolated Rat Intestinal Mitochondria M Metal Ion Stimulation of Phospholipase D-Like Activity of Isolated Rat Intestinal Mitochondria M. Madesh and K.A. Balasubramanian* The Wellcome Trust Research Laboratory, Department of Gastrointestinal Sciences, Christian Medical College & Hospital, Vellore 632 004, India ABSTRACT: Presence of phospholipase D-like (PLD) activity Under certain pathological conditions, such as oxidative in the intestinal mitochondria was identified using endogenous stress, increase in cytosolic Ca2+ occurs and this in turn in- phospholipids as substrate. The enzyme had a pH optimum of creases the Ca2+ sequestration by mitochondria (13,14). It has 6.5, did not show trans-phosphatidylation activity in the pres- been proposed that PA may act as a Ca2+ ionophore (15,16) ence of ethanol or butanol, and the product formed was phos- and facilitate the influx of Ca2+ through the plasma mem- phatidic acid (PA). This was confirmed by separation of reac- brane. Although presence of PLD activity has been shown in tion products by high-performance liquid chromatography and liver, skeletal muscle and brain mitochondria, very little is analysis of composition of the PA formed which gave phos- phate/fatty acid ratio of 1:2. PLD-like activity was further con- known on the properties of mitochondrial enzyme (17–19). firmed by the formation of ethanolamine and choline as prod- Since mitochondria are important in calcium homeostasis and ucts of enzyme action. This activity was stimulated by various PA might play a role in this process, the present study looks metal ions; when stimulated by Mg2+ and Ba2+, it hydrolyzed at the possible presence of PLD-like activity and its proper- both phosphatidylcholine and phosphatidylethanolamine, and ties in the intestinal mitochondria. when stimulated by Ca2+, it preferentially hydrolyzed phos- phatidylethanolamine. There was no requirement for sodium oleate for the PLD-like activity in mitochondria. These results MATERIALS AND METHODS suggest that intestinal mitochondria have an active PLD-like en- Various lipid standards, Hepes, fluorescamine, p-bro- zyme which differs in certain properties from phospholipase D mophenacylbromide (pBPB), chlorpromazine (CHLP), and from other tissues. bovine serum albumin (BSA) were all obtained from Sigma Lipids 32, 471–479 (1997). Chemical Company (St. Louis, MO). Standard phos- phatidylethanol and phosphatidylbutanol were prepared using A number of studies have shown that phosphatidic acid (PA) egg phosphatidylcholine and cabbage PLD in presence of is involved in cell signaling (1,2). PA can either be formed by ethanol or butanol (20). All other chemicals used were of an- the action of phospholipase D (PLD) on phospholipids or by alytical grade. phosphorylation of diacylglycerol. PLD can be activated in Preparation of mitochondria. Rats weighing 150–200 g, response to various stimuli and phorbol esters activate PLD fasted overnight, were decapitated, the small intestine re- through protein kinase C (3,4). Protein kinase C activation of moved and washed with ice-cold saline. Mitochondria were PLD takes place by both phosphorylation-dependent and in- isolated from enterocytes as described by Masola and Evered dependent mechanisms (5,6). Lipopolysaccharide stimulates (21). Isolated mitochondrial fraction was suspended in cellular PLD activity, and this requires an increase in intra- EGTA-free medium containing 250 mM sucrose/5 mM Hepes cellular Ca2+ (7). Exposure to oxygen-derived free radicals pH 7.4 and stored in ice at protein concentration of 8–10 also stimulates cellular PLD activity (8,9). Using PLD from mg/mL. Isolated mitochondria were relatively pure as judged various sources, it has been shown that divalent metal ions by the mitochondrial marker enzyme succinic dehydrogenase. can activate this enzyme (10,11). Microsomal and lysosomal contamination in the mitochon- Calcium plays an important role in many cellular func- drial preparation were checked by assaying marker enzymes, tions, and intracellular calcium is stored mainly in endoplas- namely, glucose-6-phosphatase, acid phosphatase and aryl- mic reticulum and to a small extent in the mitochondria (12). sulfatase, and these activities were not detectable. Protein was measured using BSA as standard (22). Enzyme assay. Mitochondrial PLD-like activity was mea- *To whom correspondence should be addressed. sured using endogenous mitochondrial phospholipids as sub- Abbreviations: PA, phosphatidic acid; pBPB, p-bromophenacylbromide; strate. Mitochondria (1 mg protein per mL in 0.25 M sucrose, PLD, phospholipase D; DAG, diacylglycerol; CHLP, chlorpromazine; TLC, thin-layer chromatography; HPLC, high-performance liquid chromatogra- 5 mM Hepes buffer pH 7.4) were incubated at 37°C for 30 phy; PE, phosphatidylethanolamine; PC, phosphatidylcholine. min. Following incubation, total lipids were extracted by Copyright © 1997 by AOCS Press 471 Lipids, Vol. 32, no. 5 (1997) 472 M. MADESH AND K.A. BALASUBRAMANIAN Bligh and Dyer’s method (23) and the PA was separated by by vol). This was identified after exposure to iodine vapor thin-layer chromatography (TLC) and quantitated by phos- (29). phate estimation. Extracted lipids were spotted on silica gel Lipid analysis. Neutral lipids were separated on silica gel G plates impregnated with 0.5 M oxalic acid and separated G plates using the solvent system hexane/diethyl ether/acetic using the solvent system chloroform/methanol/conc. HCl acid (80:20:1, by vol). Spots were identified by iodine expo- (85:13:0.5, by vol) (24). PA spots corresponding to standard sure, scraped, and eluted. Cholesterol (30), diglycerides, and were identified by iodine exposure, scraped, and eluted from triglycerides (31) were estimated as described. Free fatty the plates. PA was quantitated by phosphate estimation after acids were methylated and quantitated by gas chromatogra- acid digestion (25). PA formed was also separated and iden- phy after separation on a 5% EGSS-X column. Heptade- tified along with standard using two other solvent systems canoic acid was used as internal standard. Individual phos- (26,27). Formation of PA was further confirmed by separa- pholipids were separated on silica gel H plates using the sol- tion of extracted lipids on TLC followed by isolated PA spot vent system chloro-form/methanol/acetic acid/water separated by high-performance liquid chromatography (25:15:4:2, by vol) (32) and quantitated by phosphate esti- (HPLC) (28). A normal-phase silica 5-µm column was used mation after acid hydrolysis. Individual aminophospholipids with the solvent gradient of 1–9% water in hexane/2- were also quantitated after derivatization with fluorescamine propanol (3:4, vol/vol) at a flow rate of 1 mL/min and the and separation on silica gel H plates impregnated with eluents monitored at 220 nm. Transphosphatidylation was 3% magnesium acetate using the solvent system chloro- checked by inclusion of 300 mM ethanol or butanol in the form/methanol/NH4OH/water (60:40:5:2, by vol) (33). incubation mixture, and extracted lipids were separated on Eluted individual spots were quantitated using Shimadzu SF silica gel G plates using the upper phase of ethyl ace- 5000 spectrofluorometer (Tokyo, Japan) with excitation at tate/isooctane/acetic acid/water (13:2:3:10, by vol) (27). PA 395 nm and emission at 468 nm. formation in the presence of ethanol was further checked by Separation and analysis of ethanolamine. Following incu- HPLC. Metal ion stimulation of phosphatidylcholine degra- bation, enzyme activity was terminated with 10% trichloro- dation generated choline which was separated by TLC, using acetic acid. After cooling on ice, the mixture was transferred the solvent system methanol/0.6% NaCl/ammonia (50:50:5, FIG. 2. Thin-layer chromatographic separation of phosphatidic acid (PA) and phosphatidylethanol. Silica gel G plate was developed using the upper phase of the solvent system ethylacetate/isooctane/acetic FIG. 1. Effect of various metal ions (at 0.1 and 1 mM final concentra- acid/water (13:2:3:10, by vol). Lane 1 contains PA and phos- tion) on phospholipase D activity of intestinal mitochondria. Each value phatidylethanol standard. Lane 2 represents Ca2+-activated mitochon- represents mean ± SEM of three separate estimations. *P < 0.05 versus drial PA formation in the absence of ethanol. Lane 3 represents PA for- control (CON) incubated mitochondria. mation by Ca2+ activation in presence of 200 mM ethanol. Lipids, Vol. 32, no. 5 (1997) METAL ION STIMULATION OF PHOSPHOLIPASE D-LIKE ACTIVITY 473 FIG. 3. High-performance liquid chromatography separation of phosphatidic acid formed in mitochondria; (A) standard phosphatidic acid and phosphatidylethanol; (B) unincubated mito- chondria; (C) mitochondria incubated with 1 mM Ca2+; (D) mitochondria incubated with 1 mM Ca2+ + 200 mM ethanol. Total lipids were extracted. Phosphatidic acid separated by thin- layer chromatography was eluted and run on high-performance liquid chromatography as de- scribed in the text. Lipids, Vol. 32, no. 5 (1997) 474 M. MADESH AND K.A. BALASUBRAMANIAN TABLE 1 Composition of Isolated Phosphatidic Acida 2+ Co C30 +Ca Phosphate (nmole) 10.50 20.98 60.70 Fatty acids (nmole) 16:0 10.00 18.75 57.45 18:0 and 18:1 5.70 10.10 28.45 18:2 6.26 8.45 15.20 20:4 3.10 5.40 19.00 Total fatty acid 25.56 42.70 120.05 Ratio of phosphate to fatty acid 1:2.24 1:2.03 1:1.97 a Co: Control unincubated mitochondria; C30: mitochondria incubated for 30 min without any acti- vator. For calcium activation, mitochondria were incubated with 1 mM Ca2+ for 30 min. to a test tube, shaken on a vortex mixer for a minute, left for presence of Mg2+ + ethanol and 53.9 ± 1.9 in presence of Mg2+ 15 min and then centrifuged. The sediment was washed twice alone). Figure 2 shows the TLC separation of PA and phos- with 2 mL of 3% trichloroacetic acid and the supernatants phatidylethanol after Ca2+ activation of mitochondrial PLD- pooled together. Trichloroacetic acid from the supernatant like activity which showed the absence of phosphatidylethanol was removed by repeated extraction with diethyl ether, and formation in the presence of ethanol.
Recommended publications
  • Tepzz¥5Z5 8 a T
    (19) TZZ¥Z___T (11) EP 3 505 181 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.07.2019 Bulletin 2019/27 A61K 38/46 (2006.01) C12N 9/16 (2006.01) (21) Application number: 18248241.4 (22) Date of filing: 28.12.2018 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • DICKSON, Patricia GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Torrance, CA California 90502 (US) PL PT RO RS SE SI SK SM TR • CHOU, Tsui-Fen Designated Extension States: Torrance, CA California 90502 (US) BA ME • EKINS, Sean Designated Validation States: Brooklyn, NY New York 11215 (US) KH MA MD TN • KAN, Shih-Hsin Torrance, CA California 90502 (US) (30) Priority: 28.12.2017 US 201762611472 P • LE, Steven 05.04.2018 US 201815946505 Torrance, CA California 90502 (US) • MOEN, Derek R. (71) Applicants: Torrance, CA California 90502 (US) • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (74) Representative: J A Kemp Torrance, CA 90502 (US) 14 South Square • Phoenix Nest Inc. Gray’s Inn Brooklyn NY 11215 (US) London WC1R 5JJ (GB) (54) PREPARATION OF ENZYME REPLACEMENT THERAPY FOR MUCOPOLYSACCHARIDOSIS IIID (57) The present disclosure relates to compositions for use in a method of treating Sanfilippo syndrome (also known as Sanfilippo disease type D, Sanfilippo D, mu- copolysaccharidosis type IIID, MPS IIID). The method can entail injecting to the spinal fluid of a MPS IIID patient an effective amount of a composition comprising a re- combinant human acetylglucosamine-6-sulfatase (GNS) protein comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and having the en- zymatic activity of the human GNS protein.
    [Show full text]
  • Comparative Study of Idursulfase Beta and Idursulfase in Vitro and in Vivo
    Journal of Human Genetics (2017) 62, 167–174 OPEN Official journal of the Japan Society of Human Genetics www.nature.com/jhg ORIGINAL ARTICLE Comparative study of idursulfase beta and idursulfase in vitro and in vivo Chihwa Kim1, Jinwook Seo2, Yokyung Chung2, Hyi-Jeong Ji3, Jaehyeon Lee2, Jongmun Sohn2, Byoungju Lee2 and Eui-cheol Jo1 Hunter syndrome is an X-linked lysosomal storage disease caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), leading to the accumulation of glycosaminoglycans (GAGs). Two recombinant enzymes, idursulfase and idursulfase beta are currently available for enzyme replacement therapy for Hunter syndrome. These two enzymes exhibited some differences in various clinical parameters in a recent clinical trial. Regarding the similarities and differences of these enzymes, previous research has characterized their biochemical and physicochemical properties. We compared the in vitro and in vivo efficacy of the two enzymes on patient fibroblasts and mouse model. Two enzymes were taken up into the cell and degraded GAGs accumulated in fibroblasts. In vivo studies of two enzymes revealed similar organ distribution and decreased urinary GAGs excretion. Especially, idursulfase beta exhibited enhanced in vitro efficacy for the lower concentration of treatment, in vivo efficacy in the degradation of tissue GAGs and improvement of bones, and revealed lower anti-drug antibody formation. A biochemical analysis showed that both enzymes show largely a similar glycosylation pattern, but the several peaks were different and quantity of aggregates of idursulfase beta was lower. Journal of Human Genetics (2017) 62, 167–174; doi:10.1038/jhg.2016.133; published online 10 November 2016 INTRODUCTION secreted protein and contains eight N-linked glycosylation sites at Mucopolysaccharidosis II (MPS II, Hunter syndrome; OMIM 309900) positions 31, 115, 144, 246, 280, 325, 513 and 537.
    [Show full text]
  • Sanfilippo Disease Type D: Deficiency of N-Acetylglucosamine-6- Sulfate Sulfatase Required for Heparan Sulfate Degradation
    Proc. Nat!. Acad. Sci. USA Vol. 77, No. 11, pp. 6822-6826, November 1980 Medical Sciences Sanfilippo disease type D: Deficiency of N-acetylglucosamine-6- sulfate sulfatase required for heparan sulfate degradation (mucopolysaccharidosis/keratan sulfate/lysosomes) HANS KRESSE, EDUARD PASCHKE, KURT VON FIGURA, WALTER GILBERG, AND WALBURGA FUCHS Institute of Physiological Chemistry, Waldeyerstrasse 15, D-4400 Mfinster, Federal Republic of Germany Communicated by Elizabeth F. Neufeld, July 10, 1980 ABSTRACT Skin fibroblasts from two patients who had lippo syndromes and excreted excessive amounts of heparan symptoms of the Sanfilippo syndrome (mucopolysaccharidosis sulfate and keratan sulfate in the urine. His fibroblasts were III) accumulated excessive amounts of hean sulfate and were unable to desulfate N-acetylglucosamine-6-sulfate and the unable to release sulfate from N-acety lucosamine)--sulfate linkages in heparan sulfate-derived oligosaccharides. Keratan corresponding sugar alcohol (17, 18). It was therefore suggested sulfate-derived oligosaccharides bearing the same residue at that N-acetylglucosamine-6-sulfate sulfatase is involved in the the nonreducing end and p-nitrophenyl6sulfo-2-acetamido- catabolism of both types of macromolecules. 2-deoxy-D-ucopyranoside were degraded normally. Kinetic In this paper, we describe a new disease, tentatively desig- differences between the sulfatase activities of normal fibro- nated Sanfilippo disease type D, that is characterized by the blasts were found. These observations suggest that N-acetyl- excessive excretion glucosamine4-6sulfate sulfatase activities degrading heparan clinical features of the Sanfilippo syndrome, sulfate and keratan sulfate, respectively, can be distinguished. of heparan sulfate, and the inability to release inorganic sulfate It is the activity directed toward heparan sulfate that is deficient from N-acetylglucosamine-6-sulfate residues of heparan sul- in these patients; we propose that this deficiency causes Sanfi- fate-derived oligosaccharides.
    [Show full text]
  • Letters to Nature
    letters to nature Received 7 July; accepted 21 September 1998. 26. Tronrud, D. E. Conjugate-direction minimization: an improved method for the re®nement of macromolecules. Acta Crystallogr. A 48, 912±916 (1992). 1. Dalbey, R. E., Lively, M. O., Bron, S. & van Dijl, J. M. The chemistry and enzymology of the type 1 27. Wolfe, P. B., Wickner, W. & Goodman, J. M. Sequence of the leader peptidase gene of Escherichia coli signal peptidases. Protein Sci. 6, 1129±1138 (1997). and the orientation of leader peptidase in the bacterial envelope. J. Biol. Chem. 258, 12073±12080 2. Kuo, D. W. et al. Escherichia coli leader peptidase: production of an active form lacking a requirement (1983). for detergent and development of peptide substrates. Arch. Biochem. Biophys. 303, 274±280 (1993). 28. Kraulis, P.G. Molscript: a program to produce both detailed and schematic plots of protein structures. 3. Tschantz, W. R. et al. Characterization of a soluble, catalytically active form of Escherichia coli leader J. Appl. Crystallogr. 24, 946±950 (1991). peptidase: requirement of detergent or phospholipid for optimal activity. Biochemistry 34, 3935±3941 29. Nicholls, A., Sharp, K. A. & Honig, B. Protein folding and association: insights from the interfacial and (1995). the thermodynamic properties of hydrocarbons. Proteins Struct. Funct. Genet. 11, 281±296 (1991). 4. Allsop, A. E. et al.inAnti-Infectives, Recent Advances in Chemistry and Structure-Activity Relationships 30. Meritt, E. A. & Bacon, D. J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277, 505± (eds Bently, P. H. & O'Hanlon, P. J.) 61±72 (R. Soc. Chem., Cambridge, 1997).
    [Show full text]
  • Recombinant Human Arylsulfatase B/ARSB
    Recombinant Human Arylsulfatase B/ARSB Catalog Number: 4415-SU DESCRIPTION Source Chinese Hamster Ovary cell line, CHO­derived Ser37­Met533, with a C­terminal 10­His tag Accession # P15848 N­terminal Sequence Ser37 Analysis Predicted Molecular 57 kDa Mass SPECIFICATIONS SDS­PAGE 80 kDa, reducing conditions Activity Measured by its ability to hydrolyze the substrate 4­Nitrocatechol Sulfate (PNCS). The specific activity is >3,000 pmol/min/µg, as measured under the described conditions. Endotoxin Level <1.0 EU per 1 μg of the protein by the LAL method. Purity >95%, by SDS­PAGE under reducing conditions and visualized by silver stain. Formulation Supplied as a 0.2 μm filtered solution in Tris and NaCl. See Certificate of Analysis for details. Activity Assay Protocol Materials l Assay Buffer: 50 mM MES, pH 6.5 l Recombinant Human Arylsulfatase B/ARSB (rhARSB) (Catalog # 4415­SU) l Substrate: 4­Nitrocatechol Sulfate (4­PNCS) (Sigma, Catalog # N­7251) l NaOH (Sigma, Catalog # S­0899) l 96­well Clear Plate (Costar, Catalog # 92592) l Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent Assay 1. Dilute rhARSB to 1 µg/mL in Assay Buffer. 2. Dilute Substrate to 2 mM in Assay Buffer. 3. Combine 75 µL of 1 µg/mL rhARSB and 75 µL of 2 mM Substrate. Include a Substrate Blank containing 75 µL Assay Buffer and 75 µL Substrate. 4. Incubate at 37 °C for 1 hour. 5. Stop reaction by adding 150 µL of 0.2 M NaOH. 6. Load 200 µL of reaction into a plate. 7. Read at 510 nm (absorbance) in endpoint mode.
    [Show full text]
  • Genes for Degradation and Utilization of Uronic Acid-Containing Polysaccharides of a Marine Bacterium Catenovulum Sp
    Genes for degradation and utilization of uronic acid-containing polysaccharides of a marine bacterium Catenovulum sp. CCB-QB4 Go Furusawa, Nor Azura Azami and Aik-Hong Teh Centre for Chemical Biology, Universiti Sains Malaysia, Bayan Lepas, Penang, Malaysia ABSTRACT Background. Oligosaccharides from polysaccharides containing uronic acids are known to have many useful bioactivities. Thus, polysaccharide lyases (PLs) and glycoside hydrolases (GHs) involved in producing the oligosaccharides have attracted interest in both medical and industrial settings. The numerous polysaccharide lyases and glycoside hydrolases involved in producing the oligosaccharides were isolated from soil and marine microorganisms. Our previous report demonstrated that an agar-degrading bacterium, Catenovulum sp. CCB-QB4, isolated from a coastal area of Penang, Malaysia, possessed 183 glycoside hydrolases and 43 polysaccharide lyases in the genome. We expected that the strain might degrade and use uronic acid-containing polysaccharides as a carbon source, indicating that the strain has a potential for a source of novel genes for degrading the polysaccharides. Methods. To confirm the expectation, the QB4 cells were cultured in artificial seawater media with uronic acid-containing polysaccharides, namely alginate, pectin (and saturated galacturonate), ulvan, and gellan gum, and the growth was observed. The genes involved in degradation and utilization of uronic acid-containing polysaccharides were explored in the QB4 genome using CAZy analysis and BlastP analysis. Results. The QB4 cells were capable of using these polysaccharides as a carbon source, and especially, the cells exhibited a robust growth in the presence of alginate. 28 PLs and 22 GHs related to the degradation of these polysaccharides were found in Submitted 5 August 2020 the QB4 genome based on the CAZy database.
    [Show full text]
  • Phosphatidylinositide 3-Kinase Localizes to Cytoplasmic Lipid Bodies in Human Polymorphonuclear Leukocytes and Other Myeloid-Derived Cells
    PHAGOCYTES Phosphatidylinositide 3-kinase localizes to cytoplasmic lipid bodies in human polymorphonuclear leukocytes and other myeloid-derived cells Wengui Yu, Jessica Cassara, and Peter F. Weller Phosphatidylinositide 3-kinase (PI3K) is a U937 monocyte cells, PI3K p85 regulatory bodies induced to form in human polymor- key enzyme implicated in intracellular and p110␤ catalytic subunits were local- phonuclear leukocytes. These findings, signaling of diverse cellular responses ized to lipid bodies by immunocytochem- therefore, indicate a novel site for PI3K including receptor-mediated responses istry and/or immunoblotting and enzyme compartmentalization and suggest that and neutrophil activation. Several PI3K assays of subcellular fractions. In RAW PI3K-mediated signaling is active within subunits have been cloned and shown to murine macrophages, p55, p85␣, and cytoplasmic lipid bodies in leukocytes. be localized to plasma membrane recep- p85␤ PI3K subunits were present at (Blood. 2000;95:1078-1085) tors, the cytosol, or intracellular vesicles isolated lipid bodies. PI3K p85 was also or caveolae. We report the localization of shown to colocalize and, by co-immuno- PI3K to a distinct intracellular site, cyto- precipitation, to be physically associated plasmic lipid bodies, in leukocytes. In with phosphorylated Lyn kinase in lipid ௠ 2000 by The American Society of Hematology Introduction Lipid bodies are distinct lipid-rich cytoplasmic inclusions that may position of the inositol ring to produce PI(3)P, PI(3,4)P2,or 1,2 25,26 be present in
    [Show full text]
  • Table S3: List of EGFR Pathway-Regulated Genes. Gene Name Fold Fold
    Table S3: List of EGFR pathway-regulated genes. Gene Name Fold Fold EGF4h/Control EGF12h/Control Up-regulated by EGFR activation Increased at 4 hours but declined at 12 hours A kinase (PRKA) anchor protein (gravin) 12 7.67 1.58 Ab2-427 3.05 0.99 acyl-CoA synthetase long-chain family member 1 3.88 0.94 acyl-CoA synthetase long-chain family member 4 6.25 3.58 adipose differentiation-related protein 5.46 3.51 Aldehyde dehydrogenase family 1, subfamily A3 38.45 1.78 amphiregulin 77.79 27.77 arginase 1 4.10 2.06 arginosuccinate synthetase 3.00 1.19 aryl hydrocarbon receptor 5.03 1.55 ATPase, Ca++ transporting, plasma membrane 1 4.08 2.31 basic helix-loop-helix domain containing, class B2 7.86 4.12 Basophilic leukemia expressed sequence 06 (Bles06) 2.89 1.17 BH3 interacting domain death agonist 3.09 1.17 brain-specific angiogenesis inhibitor 1-associated protein 2 7.73 2.80 breast cancer anti-estrogen resistance 3 (predicted) 3.71 1.85 bridging integrator 1 6.07 2.08 cellular retinoic acid binding protein 2 2.47 1.11 charged amino acid rich leucine zipper 1 (predicted) 2.22 1.25 chemokine (C-C motif) ligand 2 3.29 1.34 chemokine (C-C motif) ligand 20 5.91 0.98 Chemotactic protein-3 3.82 -2.1 cryptochrome 1 (photolyase-like) 2.99 0.51 cyclin H 2.26 1.34 cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 3.25 1.25 cysteine knot superfamily 1, BMP antagonist 1 20.20 3.28 cytokine receptor-like factor 1 (predicted) 5.43 1.23 death-associated kinase 2 (predicted) 5.03 3.07 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 (predicted) 2.46 1.38 decay
    [Show full text]
  • Reversible and Mechanism-Based Irreversible Inhibitor Studies on Human Steroid Sulfatase and Protein Tyrosine Phosphatase 1B
    Reversible and Mechanism-Based Irreversible Inhibitor Studies on Human Steroid Sulfatase and Protein Tyrosine Phosphatase 1B by F. Vanessa Ahmed A thesis presented to the University of Waterloo in fulfilment of the thesis requirement for the degree of Doctor of Philosophy in Chemistry Waterloo, Ontario, Canada, 2009 © F. Vanessa Ahmed 2009 Author’s Declaration I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, including any required final revisions, as accepted by my examiners. I understand that my thesis may be made electronically available to the public. ii Abstract The development of reversible and irreversible inhibitors of steroid sulfatase (STS) and protein tyrosine phosphatase 1B (PTP1B) is reported herein. STS belongs to to the aryl sulfatase family of enzymes that have roles in diverse processes such as hormone regulation, cellular degradation, bone and cartilage development, intracellular communication, and signalling pathways. STS catalyzes the desulfation of sulfated steroids which are the storage forms of many steroids such as the female hormone estrone. Its crucial role in the regulation of estrogen levels has made it a therapeutic target for the treatment of estrogen-dependent cancers. Estrone sulfate derivatives bearing 2- and 4- mono- and difluoromethyl substitutions were examined as quinone methide-generating suicide inhibitors of STS with the goal of developing these small molecules as activity- based probes for proteomic profiling of sulfatases. Kinetic studies suggest that inhibition by the monofluoro derivatives is a result of a quinone methide intermediate that reacts with active-site nucleophiles. However, the main inhibition pathway of the 4- difluoromethyl derivative involved an unexpected process in which initially formed quinone methide diffuses from the active site and decomposes to an aldehyde in solution which then acts as a potent, almost irreversible STS inhibitor.
    [Show full text]
  • Organic Chemistry Option II: Chemical Biology
    Dr Stuart Conway Organic Option II: Chemical Biology University of Oxford Organic Chemistry Option II: Chemical Biology Dr Stuart Conway Department of Chemistry, Chemistry Research Laboratory, University of Oxford email: [email protected] Teaching webpage (to download hand-outs): http://conway.chem.ox.ac.uk/Teaching.html Recommended books: Biochemistry 4th Edition by Voet and Voet, published by Wiley, ISBN: 978-0-470-57095-1. Foundations of Chemical Biology by Dobson, Gerrard and Pratt, published by OUP (primer) ISBN: 0-19-924899-0 1 Dr Stuart Conway Organic Option II: Chemical Biology University of Oxford Naturally occurring amino acids slide 66 Protein structure –α-helices slide 67 • Only one helical polypeptide conformation has simultaneously allowed conformational angles and a favourable hydrogen-binding pattern. • This striking element of secondary structure is known as the α-helix. 2 Dr Stuart Conway Organic Option II: Chemical Biology University of Oxford Protein structure – anti-parallel β-sheets slide 68 O H Phe O H Phe O H N N N N N Lys O H Val O H Gln Trp H O Thr H O Gln N N N N N H O Ala H O Ile H • Anti-parallel β-sheets are an important type of protein secondary structure. • This arrangement results in a strong hydrogen bond with a near optimal N-O distance. Protein structure – parallel β-sheets slide 69 O H Phe O H Asp N N N N N H Leu O H Ile O H O H Asp O H Trp O H Ala N N N N N N Leu O H Ile O H Ile O H • β-sheets can also have a parallel arrangement.
    [Show full text]
  • Subject Index Proc
    Subject Index Proc. Natl. Acad. Sci. USA 87 (1990) 10129 Guanine adduct Purification of a factor capable of stimulating the guanine nucleotide Acetylaminofluorene bound to different guanines of the sequence exchange reaction of ras proteins and its effect on ras-related small -GGCGCC- is excised with different efficiencies by the UvrABC molecular mass G proteins, 8008 excision nuclease in a pattern not correlated to the potency of mutation Posttranslationally processed structure of the human platelet protein smg induction, 191 p21B: Evidence for geranylgeranylation and carboxyl methylation of the C-terminal cysteine, 8960 Guanine nucleotide binding Increased conversion of phosphatidylinositol to phosphatidylinositol a-Tubulin influences nucleotide binding to ,-tubulin: An assay using phosphate in Dictyostelium cells expressing a mutated ras gene, 9197 picomoles of unpurified protein, 5041 Molecular cloning of the gene for the human placental GTP-binding Guanine nucleotide-binding protein, l00-kDa protein Gp (G25K): Identification of this GTP-binding protein as the Microsomal and cytosolic fractions of guinea pig hepatocytes contain human homolog of the yeast cell-division-cycle protein CDC42, 9853 100-kilodalton GTP-binding proteins reactive with antisera against a Guanine nucleotide-exchange factor subunits of stimulatory and inhibitory heterotrimeric GTP-binding Central.prolactin infusions stimulate maternal behavior in steroid-treated, proteins, 6321 nulliparous female rats, 8003 Guanine nucleotide-binding protein, heterotrimeric Guanine
    [Show full text]
  • Supplementary File 1 (PDF, 225 Kib)
    ("autophagy"[MeSH Terms] OR "autophagy"[All Fields] OR "lysosomes"[MeSH Terms] OR "lysosomes"[All Fields] OR (lysosomal[All Fields] AND ("enzymes"[MeSH Terms] OR "enzymes"[All Fields] OR "enzyme"[All Fields])) OR "mitochondrial degradation"[MeSH Terms] OR ("mitochondrial"[All Fields] AND "degradation"[All Fields]) OR "mitochondrial degradation"[All Fields] OR "mitophagy"[All Fields] OR (AGA[All Fields] OR ("aspartylglucosylaminase"[MeSH Terms] OR "aspartylglucosylaminase"[All Fields] OR "aspartylglucosaminidase"[All Fields])) OR (ARSA[All Fields] OR ("arylsulphatase a"[All Fields] OR "cerebroside-sulfatase"[MeSH Terms] OR "cerebroside-sulfatase"[All Fields] OR "arylsulfatase a"[All Fields])) OR (ARSB[All Fields] OR ("arylsulphatase b"[All Fields] OR "n- acetylgalactosamine-4-sulfatase"[MeSH Terms] OR "n-acetylgalactosamine-4-sulfatase"[All Fields] OR "arylsulfatase b"[All Fields])) OR (ASAH1[All Fields] OR ("ceramidases"[MeSH Terms] OR "ceramidases"[All Fields] OR "n acylsphingosine amidohydrolase"[All Fields])) OR ATP13A2[All Fields] OR CLN3[All Fields] OR CLN5[All Fields] OR CLN6[All Fields] OR CLN8[All Fields] OR (CTNS[All Fields] OR cystinosin[All Fields]) OR (CTSA[All Fields] OR "cathepsin a"[MeSH Terms] OR "cathepsin a"[All Fields]) OR (CTSD[All Fields] OR "cathepsin d"[MeSH Terms] OR "cathepsin d"[All Fields]) OR (CTSF[All Fields] OR "cathepsin f"[MeSH Terms] OR "cathepsin f"[All Fields]) OR (CTSF[All Fields] OR "cathepsin f"[MeSH Terms] OR "cathepsin f"[All Fields]) OR DNAJC5[All Fields] OR (FUCA1[All Fields] OR (("alpha-l-fucosidase"[MeSH
    [Show full text]